From Yahoo Finance: 2025-04-11 05:46:00

On Thursday, traders heavily sold down Charles River Laboratories International, Inc. (CRL) by 28.13%, closing at $99.95 per share. The drop came after the FDA announced the phase-out of animal testing requirements in favor of Artificial Intelligence methods, impacting the company’s specialization in traditional animal trials.

The stock market experienced a turbulent day, with the Nasdaq dropping 4.31%, the S&P 500 falling 3.46%, and the Dow Jones down 2.50%. President Trump’s announcement of increased tariffs on Chinese goods to 145% led to a sell-off frenzy among investors, wiping out earlier gains.

Amid market volatility, 10 companies recorded double-digit losses on Thursday. Investors sought to minimize risks, resulting in heavy selling. We’ve compiled a list of the top 10 worst performers, shedding light on the reasons behind their significant downturn.

The FDA’s decision to transition from animal testing to AI methods aims to enhance drug safety and reduce research and development costs, potentially lowering drug prices. Charles River Laboratories International, Inc. faces challenges adapting to this shift, leading to a substantial drop in share prices on Thursday.

While CRL ranks as the top stock heavily sold down on Thursday, investors are urged to consider the potential of AI stocks for higher returns in a shorter time frame. With AI stocks showing promise, exploring alternative investment opportunities may yield more favorable results.

Read more: Why Charles River Laboratories International, Inc. (CRL) Went Down On Thursday?